Although the pathological features of BRCA1 breast cancer and BRCA2 breast cancer reported in our study were similar to that of Western studies, the rate of triple-negative breast cancer was very high (89%) in the BRCA1 L63X mutation group. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.